Document is current
Any future updates will be listed below
-
Authors
Wang, Jianchuan https://orcid.org/0000-0002-2604-2263
Su, Yang
Iacob, Roxana E.
Engen, John R. https://orcid.org/0000-0002-6918-9476
Springer, Timothy A. https://orcid.org/0000-0001-6627-2904
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL-134723, HL-134723, HL-134723, HL-134723, HL-134723)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
- License Information
-
More Information
Article History
Received: 14 May 2019
Accepted: 22 October 2019
First Online: 2 December 2019
Competing interests
: T.A.S. is a stock owner, consultant, and board member of Morphic Therapeutic. Other authors declare no competing interest.
